Enduring Material

- https://journals.sagepub.com/doi/10.1177/24755303231199995

• To learn more about correlations between serum adiponectin levels and the severity of psoriasis

Serum Adiponectin Levels as an Independent Marker of Severity of Psoriasis: A Cross-Sectional Analysis

• Bruce Strober, MD

• The National Psoriasis Foundation designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• The National Psoriasis Foundation designates this enduring material for a maximum of 1 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Adiponectin is an adipokine, having anti-inflammatory properties, the levels of which are reduced in metabolic syndrome. In psoriasis, it plays a preventive role by inhibiting the differentiation and proliferation of keratinocytes and decreasing the levels of the signature cytokine, IL-17. The objective of this research is to find a correlation between serum adiponectin levels and the severity of psoriasis and to compare these levels amongst patients with parameters of metabolic syndrome vs those without it.

Bruce Strober, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Therapeutics, Bristol Myers Squibb, Connect Biopharma, Dermavant, Eli Lilly, Equillium, GlaxoSmithKline, Janssen, LEO Pharma, Maruho, Meiji Seika Pharma, Mindera, Novar - Consulting - Relationship Has Not Ended
AbbVie, Eli Lilly, Janssen, and Sanofi-Genzyme - Speaking - Relationship Has Not Ended
CorEvitas Psoriasis Registry - co-scientific director - Relationship Has Not Ended
AbbVie, Cara Therapeutics, the CorEvitas Psoriasis Registry, Dermavant, Dermira, and Novartis - investigator - Relationship Has Not Ended
Journal of Psoriasis and Psoriatic Arthritis - editor-in-chief - Relationship Has Not Ended

Sam Koons, NPF Staff, has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
BMS - Consulting - Relationship Has Ended

Bruce Strober, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Therapeutics, Bristol Myers Squibb, Connect Biopharma, Dermavant, Eli Lilly, Equillium, GlaxoSmithKline, Janssen, LEO Pharma, Maruho, Meiji Seika Pharma, Mindera, Novar - Consulting - Relationship Has Not Ended
• AbbVie, Eli Lilly, Janssen, and Sanofi-Genzyme - Speaking - Relationship Has Not Ended
• CorEvitas Psoriasis Registry - co-scientific director - Relationship Has Not Ended
• AbbVie, Cara Therapeutics, the CorEvitas Psoriasis Registry, Dermavant, Dermira, and Novartis - investigator - Relationship Has Not Ended
• Journal of Psoriasis and Psoriatic Arthritis - editor-in-chief - Relationship Has Not Ended

This activity is supported by educational grants from Novartis.

• The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

0 %

100 %

9/21/2023